Login to Your Account



Ferring Moves CIC Candidate Elobixibat into Phase III Trials

By Marie Powers
Staff Writer

Friday, May 3, 2013
Less than a year after licensing constipation drug elobixibat from Swedish biotech Albireo AB, Ferring Pharmaceuticals SA initiated enrollment in two Phase III trials of the investigational compound in chronic idiopathic constipation (CIC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription